BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36653509)

  • 1. Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study.
    Chiappella A; Dodero A; Evangelista A; Re A; Orsucci L; Usai SV; Castellino C; Stefoni V; Pinto A; Zanni M; Ciancia R; Ghiggi C; Rossi FG; Arcari A; Ilariucci F; Zilioli VR; Flenghi L; Celli M; Volpetti S; Benedetti F; Ballerini F; Musuraca G; Bruna R; Patti C; Leonardi F; Arcaini L; Magagnoli M; Cavallo F; Bermema A; Tucci A; Boccomini C; Ciccone G; Carniti C; Pileri SA; Corradini P
    Leukemia; 2023 Feb; 37(2):433-440. PubMed ID: 36653509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
    d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
    J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?
    Lunning MA; Horwitz S
    Curr Treat Options Oncol; 2013 Jun; 14(2):212-23. PubMed ID: 23568456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.
    Prochazka V; Faber E; Raida L; Vondrakova J; Kucerova L; Jarosova M; Indrak K; Papajik T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):63-6. PubMed ID: 19365529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.
    Dupuis J; Morschhauser F; Ghesquières H; Tilly H; Casasnovas O; Thieblemont C; Ribrag V; Bossard C; Le Bras F; Bachy E; Hivert B; Nicolas-Virelizier E; Jardin F; Bastie JN; Amorim S; Lazarovici J; Martin A; Coiffier B
    Lancet Haematol; 2015 Apr; 2(4):e160-5. PubMed ID: 26687958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHOEP-21 chemotherapy for newly diagnosed nodal peripheral T-cell lymphomas (PTCLs) in Maharaj Nakorn Chiang Mai Hospital.
    Rattarittamrong E; Norasetthada L; Tantiworawit A; Chai-Adisaksopha C; Nawarawong W
    J Med Assoc Thai; 2013 Nov; 96(11):1416-22. PubMed ID: 24428090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
    Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
    Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
    Frontzek F; Ziepert M; Nickelsen M; Altmann B; Glass B; Haenel M; Truemper L; Held G; Bentz M; Borchmann P; Dreyling M; Viardot A; Kroschinsky FP; Metzner B; Staiger AM; Horn H; Ott G; Rosenwald A; Loeffler M; Lenz G; Schmitz N
    Lancet Haematol; 2021 Apr; 8(4):e267-e277. PubMed ID: 33667420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study.
    Feng X; Guo W; Wang Y; Li J; Zhao Y; Qu L; Yan X; Li J; Guo Q; Young KH; Bai O
    Adv Ther; 2022 Jan; 39(1):532-543. PubMed ID: 34797505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
    Gkotzamanidou M; Papadimitriou CA
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
    Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
    Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
    Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
    J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
    Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
    Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Iyer SP; Foss FF
    Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients.
    Janikova A; Chloupkova R; Campr V; Klener P; Hamouzova J; Belada D; Prochazka V; Pytlik R; Pirnos J; Duras J; Mocikova H; Bortlicek Z; Kopalova N; Mayer J; Trneny M
    Ann Hematol; 2019 Aug; 98(8):1961-1972. PubMed ID: 31065733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation.
    Prochazka V; Faber E; Raida L; Papajik T; Vondrakova J; Rusinakova Z; Kucerova L; Myslivecek M; Indrak K
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Mar; 155(1):63-9. PubMed ID: 21475380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-front Therapy With CHOP Plus Etoposide in Brazilian nodal PTCL Patients: Increased Toxicity and No Survival Benefit Compared to CHOP Regimen-Results of a Real-Life Study From a Middle-Income Country.
    Lage LAPC; Brito CV; Barreto GC; Culler HF; Reichert CO; Levy D; Costa RO; Zerbini MCN; Rocha V; Pereira J
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):812-824. PubMed ID: 35869020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romidepsin-induced durable remission for relapsed nodal peripheral T-cell lymphoma with T follicular helper phenotype after allogeneic hematopoietic cell transplantation.
    Tao K; Inamoto Y; Furukawa H; Hosoba R; Takeda W; Maeshima A; Aoki J; Ito A; Tanaka T; Kim SW; Makita S; Fukuhara S; Kogure Y; Kataoka K; Izutsu K; Fukuda T
    Int J Hematol; 2023 Aug; 118(2):292-298. PubMed ID: 36807258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study.
    Brink M; Meeuwes FO; van der Poel MWM; Kersten MJ; Wondergem M; Mutsaers PGNJ; Böhmer LH; Woei-A-Jin FJSH; Visser O; Oostvogels R; Jansen PM; Plattel W; Huls GA; Vermaat JSP; Nijland M
    Blood; 2022 Sep; 140(9):1009-1019. PubMed ID: 35544601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.